Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), today announced that Ronald
Filippo has been appointed Chief Information Officer.
Mr. Filippo has more than 25 years of digital experience in the
biopharmaceutical industry and was previously Senior Vice President
Digital at Moderna, where he was responsible for technology
leadership and digital transformation across core operations during
the commercialization of the company’s COVID-19 vaccine.
Bill Sibold, Chief Executive Officer of Madrigal, stated, “Ron’s
skillset and depth of digital experience will be a tremendous asset
for Madrigal as we prepare for a first-to-market launch of
resmetirom. His appointment reflects our commitment to leveraging
AI and other digital technologies to enhance our business across
the value chain, fulfill our ambitions for long-term growth, and
innovate on behalf of patients with NASH.”
While at Moderna, Mr. Filippo led the digital function across
the company’s core operations, most recently for a breakthrough
personalized cancer vaccine, leveraging programs in AI, robotics,
and equipment automation to optimize the manufacturing cycle and
patient experience at launch. From 2008 to 2021, Mr. Filippo held
positions of increasing responsibility at Teva Pharmaceuticals from
R&D through Commercial, most recently as Head of Data and AI
Transformation for North America, where he developed a
comprehensive data and AI strategy for the company’s commercial
operations. Mr. Filippo began his career in the biopharmaceutical
industry at Schering-Plough, supporting information technology
operations in R&D and Quality. He holds a B.S. degree in
Information Systems from Thomas Jefferson University.
Mr. Filippo stated, “I look forward to working with the Madrigal
team to enhance the company’s information technology and AI
capabilities during a pivotal period of growth and transformation.
We have an exciting opportunity to build on Madrigal’s legacy of
scientific innovation with new digital strategies that will improve
care for patients with NASH.”
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a
clinical-stage biopharmaceutical company pursuing novel
therapeutics for nonalcoholic steatohepatitis (NASH), a liver
disease with high unmet medical need. Madrigal’s lead candidate,
resmetirom, is a liver-directed THR-β agonist oral therapy that is
designed to target key underlying causes of NASH. For more
information, visit www.madrigalpharma.com.
Forward Looking Statements
This communication includes “forward-looking statements” made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, that are based on Madrigal’s beliefs
and assumptions and on information currently available to it, but
are subject to factors beyond its control. Forward-looking
statements reflect management’s current knowledge, assumptions,
judgment and expectations regarding future performance or events.
Forward-looking statements include: all statements that are not
historical facts; statements regarding new digital strategies for
patient care; statements regarding the acceleration of innovative
technology such as AI across the value chain; and statements
referenced by forward-looking statement identifiers, including the
examples in the paragraph below.;.
Forward-looking statements can be identified by terms such as
“accelerate,” “achieve,” “allow,” “anticipates,” “appear,” “be,”
“believes,” “can,” “confidence,” “continue,” “could,”
“demonstrates,” ”design,” “estimates,” “expectation,” “expects,”
“forecasts,” “future,” “guide,” “goal,” “help,” “hopeful,”
“inform,” inform,” “intended,” “intends,” “may,” “might,” “on
track,” “planned,” “planning,” “plans,” “positions,” “potential,”
“powers,” “predicts,” ”predictive,” “projects,” “seeks,” “should,”
“will,” “will achieve,” “will be,” “would” or similar expressions
and the negatives of those terms.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to: the assumptions
underlying the forward-looking statements; risks of obtaining and
maintaining regulatory approvals, including, but not limited to,
potential regulatory delays or rejections; market demand for and
acceptance of our products; our ability to prevent and/or mitigate
cyber attacks, unauthorized exfiltration of data or other security
incidents; and the risks of achieving potential benefits in studies
that includes substantially more patients, and patients with
different disease states, than prior studies; the timing and
outcomes of clinical studies of resmetirom; and the uncertainties
inherent in clinical testing. Undue reliance should not be placed
on forward-looking statements, which speak only as of the date they
are made. Madrigal undertakes no obligation to update any
forward-looking statements to reflect new information, events, or
circumstances after the date they are made, or to reflect the
occurrence of unanticipated events. Please refer to Madrigal’s
submissions filed with the U.S. Securities and Exchange Commission,
or SEC, for more detailed information regarding these risks and
uncertainties and other factors that may cause actual results to
differ materially from those expressed or implied. Madrigal
specifically discusses these risks and uncertainties in greater
detail in the sections appearing in Part I, Item 1A of its Annual
Report on Form 10-K for the year ended December 31, 2022, filed
with the SEC on February 23, 2023, as amended by our Form 10-K/A
filed with the SEC on March 3, 2023, and Part II, Item 1A of its
Quarterly Reports on Form 10-Q for the quarters ended June 30, 2023
and September 30, 2023, and as updated from time to time by
Madrigal’s other filings with the SEC.
Investor Contact Alex Howarth, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Apr 2024 to May 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From May 2023 to May 2024